The DOI matches its Crossref record.
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Abstract
3001 Background: Immunotherapy with anti–PD-1 monoclonal antibodies such as pembrolizumab shows robust, durable antitumor activity in patients with advanced melanoma. Examining gene expression related to the immune response within the tumor may provide new insights into the molecular features associated with clinical response to these agents. We evaluated immune-related gene expression patterns in patients with melanoma enrolled in the phase Ib KEYNOTE-001 study. Methods: Baseline tumor biopsy samples from 19 patients with melanoma enrolled in KEYNOTE-001 were used as a discovery set. Results were validated using samples from 62 additional patients from KEYNOTE-001, of whom 51 were evaluable for response per RECIST v1.1 by central review. RNA was extracted from formalin-fixed paraffin-embedded tissue sections and analyzed using the NanoString nCounter. Two signatures, the “Interferon-gamma [IFNγ] 10-gene” and the “Expanded-immune 28-gene,” were pre-specified prior to linking NanoString data to clinical outcomes. Results: The overall response rate (ORR) was 47% in the validation cohort. Both the IFNγ and the expanded-immune signatures showed statistically significant associations with ORR (P = 0.047 and 0.027, respectively) and progression-free survival (P = 0.016 and 0.015). Analysis of top-ranked genes on the platform led to the discovery of two new signatures, “TCR-signaling” and “Denovo” that were enriched in T-cell markers and MHC Class I and II genes. Conclusions: Measuring immune-related biomarkers, including T-cell specific, antigen presentation–related, and IFNγ signaling–related genes, may allow for improved selection of patients likely to respond to anti–PD-1 therapy with pembrolizumab. Results are consistent with the hypothesis that clinical responses to PD-1 blockade occur in patients with a preexisting interferon-mediated adaptive immune response. Further confirmation of these new signatures in melanoma is required. Clinical trial information: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationSeiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
Self-citationPredictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Self-citationAllele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Metadata
- Authors
- Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M., & Daud, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-05-20
- Volume
- 33
- Issue
- 15_suppl
- Pages
- 3001-3001
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2309483848
- Cited by
- 201
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.3001
- The paper
- Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M., & Daud, A. (2015). Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.3001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.